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Introduction
Multifocal motor neuropathy (MMN) is a rare neuropa-
thy characterized by progressive asymmetric motor 
weakness with no sensory signs in the distribution of 
two or more nerves and electrophysiologically by motor 
nerve conduction blocks (CBs) outside compression 
sites [6, 7, 15]. IVIg is today the only evidence-based 
treatment [16]. According to the guidelines of the Euro-
pean Federation of Neurological Societies, IVIg 2 g/kg 
given over 2–5 days should be considered as first line 
treatment, when disability is sufficiently severe to war-
rant treatment; level A recommendation [15]. Regarding 
maintenance therapy optimal dose and treatment inter-
val are not established – consequently there is only a 
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■ Abstract  In this prospective, 
non-randomized 6-month observa-
tional study we evaluated the effi-
cacy of intravenous immunoglobu-
lin (IVIg) dose increase in patients 
with multifocal motor neuropathy 
(MMN). Diagnosis according to 
AAEM criteria, repetitive IVIg 
treatment for at least one year, per-
sistent paresis and conduction 
block, stable symptoms and find-
ings for at least six months were 
 inclusion criteria. Nine patients (7 
men) were identified and approved 
to standardized increase of IVIg 
dose. Patients were monitored 
 using clinical scores and electro-
physiological studies. Dose was in-
creased from a baseline of 0.5 g/kg 
per month [mean, range: 0.1–1.1], 
given at variable intervals [4–12 
weeks] to 1.2 g/kg per month given 
over 3 consecutive days planned for 
6 cycles. If the patients’ motor 
function did not improve after two 
cycles they entered step two: Dose 
was increased to 2 g/kg per month 
given over 5 consecutive days. The 
increased dose was maintained for 
6 months. Assessments were per-
formed by the same investigator, 
not involved in the patient’s man-
agement, at baseline, after 2 and 
 after 6 months. Following dose in-
crease, motor function significantly 
improved in 6 patients (p = 0.014), 
2 patients entered step two, 1 pa-
tient withdrew due to absent effi-
cacy. Higher doses of IVIg caused 
more side effects, however, tran-
sient and rarely severe (p = 0.014). 
IVIg dose increase may improve 
motor functions in patients with 
stable MMN on long-term IVIg 
therapy independent of baseline 
dose. Improvement of motor func-
tion was associated with shorter 
disease duration (p = 0.008), but 
not with degree of muscle atrophy 
(p = 0.483). The treatment strategy 
to try to find the lowest effective 
dose and the longest tolerated in-
terval might lead to underdosing in 
the long-term in many patients.
■ Key words  multifocal motor 
neuropathy · MMN · immuno-
globulin · IVIg · dose increase
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level C recommendation. Therapy should be guided by 
the individual response, i. e., the best future treatment 
schedule is established through trial and error. Typical 
treatment regimes are (good practice point) 1 g/kg every 
2–4 weeks, or 2 g/kg every 1–2 months [15]. One retro-
spective study in 10 selected MMN patients, suggests 
very high doses of 2 g/kg IVIg every 4 weeks (26 g/kg/
year) to decrease the number of conduction blocks, the 
extent of axonal degeneration and to promote reinner-
vation [18]. 
The dose-response relationship in MMN has not been 
explored, neither in the short- nor in the long term. It is 
difficult to evaluate due to the rarity of the disease, indi-
vidual variations in affected muscles, degree of paresis, 
disease duration, age, and treatment side effects, making 
randomization, e. g., difficult.
A retrospective analysis of 18 MMN patients followed 
at our department and treated with the strategy of try-
ing to find the lowest effective dose and the longest tol-
erated interval had revealed slowly progressive muscle 
weakness over the long-term [4.3 years (mean (0.3–
11.8)] despite IVIg treatment (submitted for publica-
tion). This was in contrast to other studies that showed 
a more stable course under regular treatment with IVIg 
[14, 18]. With 7.7 g/kg body weight IVIg in the first year 
of treatment and 4.8 g/kg body weight/year thereafter, 
our cumulative IVIg doses per year were considerably 
lower than those used by Van den Berg et al. (22.4 g/kg 
body weight in the first and 20.8 g/kg body weight in the 
following years) and Vucic et al. (21.1 g/kg body weight/
year) [14, 18].
Therefore, we proposed increasing the dose to im-
prove motor function in those patients with persistent 
paresis. Furthermore, we intended do determine predic-
tors of response to IVIg dose increase. 
Approval of ethical committee Institutional Review 
Board (IRB) was granted for this follow-up study.
Methods 
■ Patients 
At our institution covering a population of approximately 1.5 million 
people, we follow 18 MMN patients with average disease duration of 
8.8 years (range: 1.5 to 21.8). 
 Inclusion criteria for the present study were MMN diagnosed ac-
cording to AAEM criteria, repetitive IVIg treatment for at least 1 year, 
stable IVIg dose during the last 6 months, persistent paresis and CB, 
and stable symptoms and findings for at least six months. Nine pa-
tients fulfilling these criteria consented to a standardized increase of 
IVIg dose and monitoring. Patients were monitored using clinical 
scores and electrophysiological studies. 
■ IVIg therapy
Individual IVIg dose given over the last six months was retrospec-
tively analyzed. In step one, dose was increased to 1.2 g/kg per month 
given over 3 consecutive days planned for 6 cycles. If patients’ motor 
function did not improve after 2 cycles, they entered step two: Dose 
was increased to 2 g/kg per month given over 5 consecutive days. Side 
effects and adverse events were assessed after each cycle. The follow-
ing adverse events were considered to be serious: death, all events 
requiring hospitalization, myocardial infarction, stroke, thrombosis 
and embolic disease. 
■ Follow-up evaluation
Clinical and electrophysiological assessments were performed at 
baseline, after 2 and 6 months. All clinical exams were performed by 
the same investigator, not involved in the patient’s management.
 The primary clinical outcome measure was change in motor func-
tion from baseline to 6 months scored according to the following 
scales:
 The Medical Research Council (MRC) rating scale in 40 muscles 
or muscle groups (11 in each upper limb, 9 in each lower limb) was 
assessed resulting in a maximal score of 200 for a normal strength. 
Overall weakness was assessed by taking the difference between the 
maximal score and the individual clinical score which was called MRC 
paresis sum score, where 0 means no paresis and 200 complete loss of 
motor function. 
 Functional outcome was assessed, a) using the Guy’s Neurological 
Disability Scale where 0 means no disability and 10 means no motor 
function in arms and legs [8, 14] and, b) according to our own non-
validated Individual Disability Score where three motor activities of 
daily life (e. g., binding shoe strings) were defined individually for 
each patient at baseline. A score of 0 indicated no symptoms; 1 = func-
tion slightly slowed but qualitatively unimpaired, 2 = function se-
verely slowed, 3 = function qualitatively severely impaired, 4 = func-
tion impossible, giving a total score of 0 with normal motor function 
and 12 if none of the three functions could be performed. To our 
knowledge, there is no validated individual disability score. Leger JM, 
et al. also used a non-validated own score [5].
 Secondary clinical outcome measure was muscle atrophy which 
was assessed at baseline and after 6 months according to our own 
non-validated atrophy score. Twenty-four muscle groups (7 in each 
upper limb and 5 in each lower limb) were rated according to the fol-
lowing scale: severe = 3 points (no muscle belly can be seen and felt); 
moderate = 2 points (clearly reduced muscle belly); slight = 1 point 
(slightly reduced muscle belly for age and occupation and compared 
with unaffected muscles); no atrophy = 0 points. Thus a maximal 
score of 72 would indicate complete muscle atrophy. 
■ Nerve conduction studies (NCSs)
NCSs were performed at baseline in clinically affected nerves and 
proximal stimulation (Erb’s point) was only performed if CB was not 
detected distally. CB was defined according the AAEM criteria [6]. 
Follow-up of NCSs were repeated only in nerves with proven CB.
■ Electromyography (EMG)
Needle EMG was performed at baseline and at the study end in one 
affected muscle in those patients who agreed to this investigation.
■ Definition of treatment response 
Response was defined clinically: Improvement by at least 2 points in 
MRC paresis sum score and (in addition) by at least one point either 
in the Guy’s Neurological Disability Scale or the Individual Disability 
Score. These cut-off values are in accordance to previous studies [5]. 
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■ Statistical analysis
Statistical analysis was performed using Mann-Whitney test for un-
paired and Wilcoxon Signed Ranks test for paired data between two 
groups. 
Results
■ Patients 
Mean age at study onset was 59.4 years [range: 46–80]. 
Before study, mean disease duration was 11.2 years 
[range: 2–23], mean treatment duration with IVIg was 
6.7 years [range: 1–14]. Anti-GM1 (IgM) antibodies were 
positive in 6 and negative in 3 patients (Table 1). 
■ IVIg therapy
Stable average IVIg dose over the 6 months before entry 
into the study was 0.5 g/kg per month [range: 0.1–1.1 g/
kg/month], given at variable intervals [4–12 weeks] (Ta-
ble 1). Dose was increased as described in the method 
section. 
■ Response to dose increase
Following step one, 6/9 patients improved, 2/3 non-re-
sponders entered step two and 1/3 non-responders with-
drew due to absent efficacy and stopped IVIg treatment 
but consented to follow-up. In this one patient disease 
course was stable despite suspension of therapy. The two 
entering step two did not improve. One out of 6 respond-
ers (step 1) stopped after 4 months due to side effects 
(nausea). One patient required hospitalization due to 
infection of i.v. line with septicemia (serious adverse 
event). Seven patients completed the 6 months (5 re-
sponders at 2 months and 2 non-responders after 2 and 
6 months). Mean MRC paresis sum score improved from 
28.57 [range: 6–47] to 26.29 [range: 3–46] (p = 0.048), 
mean Guy’s Neurological Disability Scale improved from 
3.86 [range: 2–6] to 3.14 [range: 0–6] (p = 0.030), mean 
Individual Disability Score improved from 9.00 [range: 
7–11] to 7.14 [range: 4–9] (p = 0.014) (Fig. 1). 
Improvement was best reflected in the Individual 
Disability Score (6), and less in MRC paresis sum score 
(5) or Guy’s Neurological Disability scale (4). One re-
sponder (case 5) reported marked improvement at 
month 2 but had deteriorated again at stable dose of 
IVIg at month 6, but was still better than at baseline. 
Mean disease duration before study entry was longer 
in non-responders (n = 3; 15.67 years, [range: 14–17]) 
compared to responders (n = 6; 9.00 years [range: 2–23]) 
which was significant (p = 0.008). Difference in muscle 
atrophy between the 3 non-responders (mean atrophy 
score 18.00 [range: 7–26]) and the 6 responders (mean 
atrophy score 16.67 [range: 2–30]) was not significant 
(p = 0.483). 
■ Side effects
One of six responders (step 1) stopped after 4 months 
due to side effects (nausea). One patient required hospi-
talization due to infection of the i.v. line with septicemia 
(serious adverse event). Six patients had side effects: fa-
tigue (5), headache (4), nausea (2), hypertension (2), ver-
tigo (1) and abdominal pain (1). Overall in 35/48 (73 %) 
of IVIg cycles with increased dose at least one side effect 
was reported; in the 6 months before dose-increase at 
least one side effect was reported in 5/39 IVIg cycles 
(13 %) (p = 0.014).
■ Electrophysiological assessment
Follow-up of nerve of conduction studies was possible 
in 8/9 patients. One patient (case 5) refused assessment 
at termination visit. Interpretation of results is possible 
in 7/9 patients as in one patient (case 2) supramaximal 
stimulation at Erb’s point was not possible. No CB com-
pletely disappeared. Response of CB’s to treatment did 
not show a consistent pattern or correlation to clinical 
response (Table 2).
Five of nine patients consented to needle EMG at 
baseline and the end of the study. Four showed incom-
plete or discrete recruitment pattern of motor units 
(MUP) at baseline which after treatment had improved 
in three. Quantitative MUP analysis (Willison analysis) 
was performed in three and showed signs of chronic ax-
onal damage without change after treatment in all; none 
had fibrillation potentials or fasciculations. Disease du-
ration in these three patients was 3, 2 and 14 years, re-
spectively.
Discussion
In this small prospective, non-randomized, uncontrolled 
study, motor function significantly improved in 6/9 pa-
tients with MMN on long-term IVIg maintenance ther-
apy by increasing IVIg dose. One patient transiently im-
proved, then worsened again, but was still better than at 
baseline. A retrospective analysis of our 18 patients with 
MMN treated with the strategy of trying to find the low-
est effective dose and the longest tolerated interval re-
vealed progressive muscle weakness during the 4.3 years 
follow-up (mean, range: 0.3–11.8) under regular IVIg 
treatment. This outcome was in contrast to other studies 
that showed a more stable course under regular treat-
ment with IVIg [14, 18]. With 7.7 g/kg body weight IVIg 
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in the first year of treatment and 4.8 g/kg body weight/
year thereafter, our cumulative IVIg doses were consid-
erably lower than those used by Van den Berg et al. with 
22.4 g/kg body weight in the first year of treatment and 
20.8 g/kg body weight thereafter. Furthermore, Van den 
Berg et al. increased the dose even more in patients with 
a functional decline [14]. Vucic et al. in a study of 10 se-
lected MMN patients showed significant long-term clin-
ical and neurophysiological improvement during an 
observation time of 7.25 years. The IVIg dose used was 
21.2 g/kg body weight/year [18]. Our results confirm that 
the efficacy of IVIg is dose dependent and that declining 
motor function can be restored by increasing IVIg dose, 
at least in 2/3 of MMN patients. Improvement correlated 
with short pretreatment disease duration indicating the 
need of higher doses of IVIg in early stages of the dis-
ease. However, dose increase does not work in all pa-
tients and might have a “ceiling effect” and thus must be 
titrated individually in each patient.
CB, the electrodiagnostic hallmark of MMN, was be-
lieved to underlie weakness in MMN. Treatment with 
IVIg may decrease the number of CB [3, 14, 18]. How-
ever, as confirmed by our results, most authors agree 
that CB status neither predicts nor runs parallel to clin-
ical treatment response [9]. Recent studies showed that 
axon loss is also an important and early feature in MMN 
and correlates with muscle weakness [13, 17]. According 
to the study of Van Asseldonk et al., axon loss and not 
conduction block is the most significant independent 
determinant of weakness in corresponding muscles [12]. 
It is therefore unclear whether improvement of CB or 
reinnervation allows for improvement of motor func-
tion. The time course with quite rapid improvement 
within two months in our patients is in favor of IVIg 
reducing CBs. Furthermore, axonal degeneration was 
found to correlate significantly with both CB and with 
muscle weakness [12, 17]. Distal CMAP amplitude evo-
lution is not optimal to determine axonal degeneration 
since a decrease in CMAP can either be due to distal CB, 
dispersion, or muscle atrophy due to inactivity or axonal 
degeneration. In our small sample, we found no sponta-
neous activity indicating ongoing denervation. Axonal 
damage could be only shown using quantitative analysis 
of motor unit potentials. We were not able to detect signs 
of axonal regeneration which probably would require a 
longer, high dose treatment phase and longer observa-
tion period [18]. Beneficial axonal regeneration is diffi-
cult to define and finally should lead to progressive and 
longstanding increase of CMAP amplitudes and reversal 
of atrophy. Vucic et al. in their highly selected patient 
group did not quantify their findings regarding axonal 
regeneration (e. g., using quantitative analysis of motor 
unit action potentials) and there is no statement about 
how many patients (instead of regions) had pretreat-
ment axonal damage and in how many of them this find-
ing disappeared. Furthermore, muscle atrophy, a fre-
quent and even early finding [11, 12], is not commented 
and the high values for pretreatment distal CMAP am-
plitudes despite disease durations between 5 and 26 
years is astonishing. The finding of axonal degeneration 
in only 16 % of muscles as compared to 61 % in the 20 
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Fig. 1  Outcome of motor function. Six patients improved in step one (solid line); 
two patients (dashed line) entered step two. Individual disability scale: 0 = best, 
12 = worst performance (1 withdrawal after 4 months due to adverse events)
 Patient Nerve Assessment of nerve conduction studies Muscle
Amplitude reduction (%) 
at site of CB
Amplitude CMAP (mV) 
with distal stimulation
baseline after 6 months baseline after 6 months
 Case 1, 63 y/M ulnar (R) 45  32 4.2 4.7 ADM (R) 
 Case 3, 47 y/F ulnar (L) 63  67 3.5 4 ADM (L)
 Case 4, 77 y/M* ulnar (L) 32  27 3.8 4.9 ADM (L)
 Case 6, 63 y/F ulnar (L) 59  54 6.6 7 ADM (L)
 Case 7, 56 y/M ulnar (R) 99  98 7.2 6.1 ADM (R) 
 Case 8, 46 y/M median (L) 72  77 4 4.7 APB (L)
 Case 9, 51 y/M radial (L) 80 100 2.5 1.5 Ext. dig. com. (R) 
ulnar ulnar nerve; radial radial nerve; APB M. abductor pollicis brevis; ADM M. abductor digiti minimi; Ext. dig. com. M. extensor 
digitorum communis; * assessment after 2 months
Table 2  Evolution of CB and distal 
CMAP
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patients studied by Van Asseldonk [12] and to our re-
sults is also in favor of a selected patient population. We, 
as well as van Asseldonk, found axonal damage already 
in patients with short disease duration of less than 4 
years. Determination of axonal damage should include 
quantitative analysis of motor unit action potentials. 
Most adverse events of IVIg are mild and transient. 
The reported incidence varies widely between 1 and 
81 % of patients treated or of applied infusions. Most 
studies report adverse events in 30 and 40 % of infusions 
[2, 4, 10]. The incidence is clearly dependent on the infu-
sion rate, but it is unclear whether it is also dose depen-
dent [1]. According to Dalakas the application of 2 g 
IVIg/kg over 2 days is not associated with more side ef-
fects than the application over 5 days [1]. We found a 
significantly higher incidence of reported adverse events 
with dose increase compared to the pre-study time with 
lower doses (73 % of cycles and 13 %, respectively; one 
withdrawal from study due to side effects and one septi-
cemia which led to hospitalization). Aside the dose, age 
might play a role which was 59.4 years [46–80] in our 
patient population. The patient who did not tolerate the 
dose increase (case 4) was 77 years old. 
The present study has several limitations: 1) non-
randomized design (lack of a control group); 2) non-
blinded evaluation; 3) non-linear scoring; 4) use of 
partly non-validated scores (atrophy score and individ-
ual disability score); 5) arbitrary defined criteria for 
treatment response; 6) small patient sample (e. g., for 
statistical analysis) and short time follow-up (6 months). 
However, randomization in this rare disease is difficult, 
long-term clinical scoring given the individually quite 
variable features and slow progression is a challenge, 
Guy’s and MRC scores are not very sensitive for focal 
weakness as frequently present in MMN, and a validated 
score for muscle atrophy is not available. In a double, 
blind trial of IVIg in MMN, disability self-reports proved 
in better agreement with overall clinical change than 
MRC estimates of strength [5].
To summarize
Increasing IVIg dose can improve motor function in 
MMN patients with persistent deficits even after a pro-
longed seemingly stable disease course. Thus, instead of 
following the widely used treatment strategy of trying to 
find the lowest effective dose and the longest tolerated 
interval, it might be more successful to find the highest 
and most effective dose tolerated and the shortest inter-
val with the highest gain of motor function. To what ex-
tent and for how long such a regimen can be pursued is 
unclear as well as whether it will work at any disease 
stage, e. g., regarding degree of axonal damage and mus-
cle atrophy, or whether IVIg can prevent or even reverse 
axonal degeneration. Considering side effects and also 
economic aspects more and better designed multicenter 
studies with larger patient samples are necessary before 
such an expensive and burdensome treatment strategy 
can be widely recommended.
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